Abstract
The purpose of the study was to evaluate clinical target (HR-CTV) coverage and OAR doses of ISBT and IS-ICBT brachytherapy techniques for cervix cancer. As this is a retrospective study, 11 patients treated from 2018 to 2022 were identified, ISBT (n=4) and IC-ISBT (n=7). Dose-volume histogram (DVH) from Oncentra Treatment Planning System and dosimetric parameters were analyzed and evaluated.The results showed the mean EQD2 of HR-CTV for both techniques were 89.1 ± 11.71 Gy while the mean EQD2 of D2cc for bladder, rectum and sigmoid were 88.9 ± 16.71 Gy, 81.2 ± 12.63 Gy, and 70.1 ± 15.95 Gy, respectively. For IC-ISBT technique, the mean EQD2 of HR-CTV was 91.5 ± 8.4 Gy which was slightly exceeds the dose constraints of 80 to 90 Gy based on ABS recommendation. HR-CTV volume that ranged from 34.93 - 168.33 cm3. The mean of CI was 0.90 and the mean of DHI for this technique was 0.36 ± 0.06. Meanwhile for ISBT technique, the mean HR-CTV volume range from 26.95 - 82.82 cm3. The mean EQD2 of HR-CTV was at 85.1 ± 16.75. The mean CI and DHI were at 0.85 ± 0.16 and 0.37 ± 0.1, respectively. As a conclusion, the mean EQD2 doses to the rectum (81.2 Gy) in both techniques slightly exceeded the limit from ABS recommendation. The mean DHI value was not quite significant different in both techniques. However, the IS-ICBT technique was more superior in conforming dose to HR-CTV based on higher CI value compared to ISBT alone.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
